Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers

[1]  Vianne R. Gao,et al.  Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer , 2020, Cancer cell.

[2]  C. Mason,et al.  Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation , 2020, Cancer cell.

[3]  Yeon-Hee Park,et al.  Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[5]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[6]  A. Zelenetz,et al.  Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Roman Schefzik,et al.  IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer , 2018, Cell Death & Disease.

[8]  A. Font,et al.  Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss , 2018, Clinical Cancer Research.

[9]  M. Rubin,et al.  Suppression of insulin feedback enhances the efficacy of PI3K inhibitors , 2018, Nature.

[10]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[11]  Dejan Juric,et al.  Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Barrett,et al.  A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers , 2017, Clinical Cancer Research.

[13]  M. Espié,et al.  Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2017, The Lancet. Oncology.

[14]  Lewis C. Cantley,et al.  The PI3K Pathway in Human Disease , 2017, Cell.

[15]  A. Armstrong,et al.  Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. , 2017, European journal of cancer.

[16]  Maurizio Scaltriti,et al.  PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D , 2017, Science.

[17]  Jeffrey A Jones,et al.  Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. , 2017, The Lancet. Haematology.

[18]  I. Treilleux,et al.  Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group , 2017, British Journal of Cancer.

[19]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[20]  K. Cornille,et al.  Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition , 2016, Breast Cancer Research.

[21]  S. Larson,et al.  Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications , 2015, Cancer.

[22]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[23]  T. Roberts,et al.  A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis , 2015, Nature Communications.

[24]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[25]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[26]  Michael G. Kharas,et al.  PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer , 2015, Science Translational Medicine.

[27]  V. Gandhi,et al.  Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma , 2015, Clinical Cancer Research.

[28]  J. Engelman,et al.  Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. , 2015, Cancer cell.

[29]  Simon T Barry,et al.  Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. , 2015, Cancer cell.

[30]  S. Barry,et al.  Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel , 2014, Molecular Cancer Therapeutics.

[31]  Obi L. Griffith,et al.  Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.

[32]  Hans Clevers,et al.  Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.

[33]  E. Cuppen,et al.  Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures , 2014, Cell.

[34]  T. Roberts,et al.  PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context , 2014, Proceedings of the National Academy of Sciences.

[35]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[36]  D. Erdmann,et al.  Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials , 2014, Molecular Cancer Therapeutics.

[37]  Christof Fellmann,et al.  An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.

[38]  G. Hampton,et al.  Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068 , 2013, Clinical Cancer Research.

[39]  Tyler T. Risom,et al.  Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models , 2013, Clinical Cancer Research.

[40]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[41]  N. Gray,et al.  Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. , 2012, Cancer discovery.

[42]  Jing Li,et al.  Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background , 2012, Molecular Cancer Therapeutics.

[43]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[44]  Cole Trapnell,et al.  Improving RNA-Seq expression estimates by correcting for fragment bias , 2011, Genome Biology.

[45]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[46]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[47]  T. Roberts,et al.  Should individual PI3 kinase isoforms be targeted in cancer? , 2009, Current opinion in cell biology.

[48]  Alice T. Loo,et al.  PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.

[49]  M. Jeschke.  Faculty Opinions recommendation of Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. , 2008 .

[50]  M. Loda,et al.  Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.

[51]  Hailing Cheng,et al.  The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation , 2006, Proceedings of the National Academy of Sciences.

[52]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[53]  J. Olefsky,et al.  Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signaling pathways. , 1996, Endocrinology.

[54]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[55]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[56]  Jing Li,et al.  Preclinical Development Preclinical Pharmacology of AZD 5363 , an Inhibitor of AKT : Pharmacodynamics , Antitumor Activity , and Correlation of Monotherapy Activity with Genetic Background , 2012 .